I consider them a decent holding in the generic sector but, if you don’t yet own any generic companies, I would recommend buying TEVA as your anchor position.
Ranbaxy will have an enormous upside if they win the Lipitor patent challenge against PFE, but most people think that’s a pretty long longshot.
News 
Market Data 
Discover 
